Shares of Valeant Pharmaceuticals jumped higher Tuesday after the drug maker maintained its full-year forecast despite a second quarter earnings miss. Earnings of $1.40 fell short of analysts’ estimates. And revenue of $2.42 billion was also below Wall Street’s forecast. Valeant reiterated its full-year earnings forecast range of $6.60 to $7 a share and revenue of roughly 10 billion dollars.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
